[go: up one dir, main page]

TW200904810A - 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester, its regio-specific synthesis and intermediate thereto - Google Patents

4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester, its regio-specific synthesis and intermediate thereto Download PDF

Info

Publication number
TW200904810A
TW200904810A TW097111151A TW97111151A TW200904810A TW 200904810 A TW200904810 A TW 200904810A TW 097111151 A TW097111151 A TW 097111151A TW 97111151 A TW97111151 A TW 97111151A TW 200904810 A TW200904810 A TW 200904810A
Authority
TW
Taiwan
Prior art keywords
methyl
propoxythiophene
carboxylic acid
coupling
reaction
Prior art date
Application number
TW097111151A
Other languages
Chinese (zh)
Inventor
Ann Marie Gelormini
John J Shay
Adam W Sledeski
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of TW200904810A publication Critical patent/TW200904810A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)

Abstract

The present invention is directed to 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2, 5-dioxo-pyrrolidin-1-yl ester, and intermediate, 3-methyl-5-propoxythiophene-2-carboxylic acid 2, 5-dioxo-pyrrolidin-1-yl ester, thereto. The present invention is also directed to the regio-specific synthesis of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2, 5-dioxo-pyrrolidin-1-yl ester compound comprising the steps of iodinating 3-methyl-thiophene with an iodinating agent in the presence of a strong base in an non-protic polar or hydrocarbon solvent to yield 2-iodo-4-methylthiophene; Ullmann coupling the 2-iodo-4-methylthiophene with an alkali metal propoxide salt using a copper catalyst in propanol to yield 4-methyl-2-propoxythiophene; coupling the 4-methyl-2-propoxythiophene with CO2 using strong base in an non-protic polar or hydrocarbon solvent to yield 3-methyl-5-propoxy-thiophene-2-carboxylic acid; esterifying the 3-methyl-5-propoxy-thiophene-2-carboxylic acid with N-hydroxysuccinimide in the presence of a coupling agent in an non-protic polar, hydrocarbon or halohydrocarbon solvent to yield 3-methyl-5-propoxythiophene-2-carboxylic acid 2, 5-dioxo-pyrrolidin-1-yl ester; and brominating the 3-methyl-5-propoxythiophene-2-carboxylic acid 2, 5-dioxo-pyrrolidin-1-yl ester with a brominating agent in an inert solvent to yield 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2, 5-dioxo-pyrrolidin-1-yl ester.

Description

200904810 九、發明說明: 【發明所屬之技術領域】 本發明^及4-溴-3_甲基_5_丙氧&塞吩领酸^二 氧料燒-1 -基酯’它在類騰蛋白酶抑f d劑[4_(5_胺基甲基_2_ 5氟苯基W定_1舟(4-填'3-曱基_5-丙氧基售吩-2-基)_曱_ 的製備過程中可作為中間體使用。本發明還涉及它的特定 區域專-性合成以及3-甲基_5_丙氧基嗟吩_2_魏酸2,5-二氧 口比口各院-l-基酯,後者在4-溴-3-甲其sa ,. 误 丙乳基噻吩-2-羧酸 2,5-二氧口比咯烧-1-基酿的製備過程中可作為中間體使用。 10 【先前技術】 wmcm/mn披露了一些化合物,包括作為類胰蛋白 酶抑制劑的[(苯曱胺)-呱啶_;!_基](芳基或雜芳基)甲酮,並敘 述了因類胰蛋白酶涉及各種生物過程包括使血管舒張和支 15 氣管鬆弛的神經肽的降解過程(Caughey,et al.,J. Pharmacol.200904810 IX. Description of the invention: [Technical field to which the invention pertains] The present invention and 4-bromo-3-methyl-5-propoxy-amp; phenoxy acid dioxane-l-yl ester Protease inhibitor fd [4_(5_Aminomethyl_2_5fluorophenyl W1) (4-filled '3-mercapto-5-propoxy phenyl-2-phenyl)_曱_ It can be used as an intermediate in the preparation process. The present invention also relates to its specific region-specific synthesis and 3-methyl-5-propoxy porphin-2_weilic acid 2,5-dioxy port Y-l-ester, the latter in the preparation of 4-bromo-3-methyl-sa,. propyl-propylthiophene-2-carboxylic acid 2,5-dioxopyrylpyrrol-1-yl Used as an intermediate. 10 [Prior Art] wmcm/mn discloses some compounds, including [(phenylhydrazine)-acridine_;!-yl](aryl or heteroaryl) A as a tryptase inhibitor Ketones, and describes the degradation of neuropeptides involved in various biological processes including tryptase and vasodilation and relaxation of the trachea (Caughey, et al., J. Pharmacol.

Exp. Ther., 1988, 244, pages 133-137; Franconi, et al., J. Pharmacol. Exp. Ther” 1988, 248, pages 947-951;以及 Tam, et al., Am. J. Respir. Cell Mol. Biol” 1990, 3, pages 27_32 )以 及對於支氣管一組胺反應性的調節過程(Sekizawa, et al., J. 2〇 Clin. Invest·,1989, 83, pages 175-179 ),從而決定的這類化 合物的潛在用途。 W02005/097780更具體地披露了結構式為A的(苯曱 胺)-呱啶-1-基噻吩基曱酮化合物,即([4-(5-胺基曱基-2-氟 苯基)-呱啶-1-基H4-溴-3-曱基-5-丙氧基噻吩-2-基)-甲酮), 200904810Exp. Ther., 1988, 244, pages 133-137; Franconi, et al., J. Pharmacol. Exp. Ther" 1988, 248, pages 947-951; and Tam, et al., Am. J. Respir. Cell Mol. Biol" 1990, 3, pages 27_32) and the regulation of a group of amine reactivity in the bronchus (Sekizawa, et al., J. 2〇 Clin. Invest·, 1989, 83, pages 175-179), thereby The potential use of such compounds is determined. WO 2005/097780 discloses more specifically a (benzoguanamine)-acridin-1-ylthienyl fluorenone compound of the formula A, ie ([4-(5-aminomercapto-2-fluorophenyl)) -Acridine-1-yl H4-bromo-3-indolyl-5-propoxythiophen-2-yl)-methanone), 200904810

它的製備方法,及其在可通過抑制類胰蛋白酶而治療的疾 病方面的用途。W02005/097780還披露,結構式為A的化 合物是通過下述化合物16與10的偶合反應,以及偶合產 物隨後的脫保護反應而製備的,如下所示Its preparation method and its use in diseases which can be treated by inhibiting tryptase. W02005/097780 also discloses that the compound of formula A is prepared by the coupling reaction of compounds 16 and 10 below, and the subsequent deprotection of the coupling product, as shown below.

中間體化合物16是按照下述多步驟製備法製備的 200904810Intermediate compound 16 was prepared according to the following multi-step preparation method.

41%41%

1111

MaH CS3;MaH CS3;

MeOMaMeOMa

MaOH 77%MaOH 77%

雖然通過上述過程也能製備中間體16,但它採用了繁 多的步驟,採用了氣味特徵令人不快的無環中間體,而且 不是從易得的噻吩基原料開始製備。此過程在化合物15的 5 酯基向化合物16中對應的酸基轉化的過程中,需要一個額 外的步驟,例如,操縱化合物16中間體中的羧基功能圑。 【發明内容】 本發明涉及4-溴-3-甲基-5-丙氧基噻吩-2-羧酸2,5-二氧 ίο 11比咯烧-1-基醋。 本發明還涉及4-溴-3-曱基-5-丙氧基噻吩-2-羧酸2,5-二 200904810 手:小基酯化合物的特定區域合成,包括以下步驟: =種_存在條件下在—種非許極性溶劑或煙溶 H用—_化劑將3·甲基^㈣化,以生成2-埃 -4-甲基噻吩; 3-種銅催化劑在丙醇中進行2鲁心甲基嗟吩與驗 至萄丙醇鹽的烏爾曼偶合反應,以生成4-甲基-2-丙氧 基噻吩; 在了種非質子極性溶劑或烴溶射用㈣使4_甲基_2_ ?氧基噻吩與co2發生偶合反應,以生成3_甲基_5-丙 氧基噻吩-2-鲮酸; ^種偶合劑存在條件下在—種非質子極性溶劑、煙 /谷劑或鹵代烴溶劑中用N_琥珀醯亞胺將3_甲基_5_丙氧 基嗲吩-2-羧酸酯化,以生成3_曱基_5_丙氧基噻吩-2_ 叛酉义2,5-一氧吼17各烧-1-基g旨;以及 在一種惰性溶劑中用一種溴化劑將3_甲基_5_丙氧基噻 呍-2-羧酸2,5-二氧吼洛烧_1_基酯溴化,以生成4_溴-3_ 曱基-5-丙氧基噻吩_2_綾酸2,5-二氧吡咯烷_ι_基酯。 本發明還進一步涉及具有以下結構式的3_曱基_5_丙氧 基噻吩-2-羧酸2,5-二氡吡咯烷基酯,Although the intermediate 16 can be prepared by the above process, it employs a wide variety of steps, using an acyclic intermediate having an unpleasant odor characteristic, and is not prepared from a readily available thiophene-based starting material. This process requires an additional step in the conversion of the 5 ester group of compound 15 to the corresponding acid group in compound 16, for example, manipulation of the carboxyl functional group in the intermediate of compound 16. SUMMARY OF THE INVENTION The present invention relates to 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxy ε 11 pyrrol-1-yl vinegar. The invention further relates to the synthesis of a specific region of 4-bromo-3-indolyl-5-propoxythiophene-2-carboxylic acid 2,5-di 200904810 hand:small ester compound, comprising the following steps: = species _ existence conditions In the case of a non-polar solvent or a solubilized H--chemical agent, 3·methyl^(tetra) is formed to form 2-A-4-methylthiophene; 3-type copper catalyst is carried out in propanol. Cardiomethyl phenanthrene is coupled with a Ullmann coupling to propylene fluoride to form 4-methyl-2-propoxythiophene; in a protic polar solvent or hydrocarbon spray (4) to make 4-methyl _2_?oxythiophene is coupled with co2 to form 3-methyl-5-propoxythiophene-2-furoic acid; in the presence of a coupling agent, in an aprotic polar solvent, smoke/trol Esterification of 3-methyl-5-propoxy porphin-2-carboxylic acid with N-succinimide in a halogenated hydrocarbon solvent to form 3-mercapto-5-propoxythiophene-2_酉 2,5-monooxo 17 each is a 1-methyl group; and 3-methyl-5-propoxythiazine-2-carboxylic acid 2 is treated with a brominating agent in an inert solvent. 5-dioxazolidine _1_yl ester is brominated to form 4_bromo-3_ decyl-5-propoxythiophene-2-indole 2,5-dioxypyridyl _Ι_ alkyl ester. The present invention still further relates to 3,5-dioxapyrrolidinyl 3-(indolyl)-5-propoxythiophene-2-carboxylic acid having the following structural formula,

它在4-溴-3-曱基-5-丙氧基噻吩_2_羧酸2,5_二氧吡咯烷4 — 200904810 基酯的製備過程中可作為中間體使用。 本發明之詳述 通過夢閱以下詳細說明將能更好地理解本發明。 定義 如上文所用以及貫穿本發明之全部說明,包括所附的 專利申請範圍,下列縮寫和術語應被理解為具有以下含 義,除非另行說明: 「鹼金屬」意為鐘、鈉、鉀或铯。 「驗金屬丙醇鹽」意為通過用一種強鹼處理丙烷而得 到的一種鹽的形式。強鹼的例子有Cs2c〇3,鹼金屬的鹼如It can be used as an intermediate in the preparation of 4-bromo-3-indolyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxypyrrolidine 4 - 200904810. DETAILED DESCRIPTION OF THE INVENTION The present invention will be better understood by the following detailed description. DEFINITIONS As used above and throughout the description of the invention, including the scope of the appended patent application, the following abbreviations and terms are understood to have the following meanings unless otherwise stated: "alkali metal" means bell, sodium, potassium or cesium. "Test metal alkoxide" means a form of a salt obtained by treating propane with a strong base. An example of a strong base is Cs2c〇3, an alkali metal base such as

NaH、NaHMDS、KHMDS、LiHMDS、二異丙醯胺鋰(LDA ), 或烷基金屬如烷基鋰、烷基鉀、烷基鈉以及烷基鎂,其中 的烷基是Cu烷基,更為首選的是丁基,例如、CsOPr、NaH, NaHMDS, KHMDS, LiHMDS, lithium diisopropylamide (LDA), or an alkyl metal such as alkyl lithium, potassium alkyl, sodium alkyl and alkyl magnesium, wherein the alkyl group is a Cu alkyl group, Preferred is butyl, for example, CsOPr,

NaOPr、LiOPr 或 KOPr。 「醯胺化偶合」意為生成一種醯胺的偶合反應。 「溴化劑」意為一種溴源,例如Br2或NBS。 「銅催化劑」意為一種能促進烏爾曼偶合反應的銅催 化劑,選自 CuSCN、CuBr、Cul、Cua、CuBF4、CuPF6、 CuOTf、CuPF6、CuBr2、CuCl2、和 Cu20。 「偶合助溶劑」意為能與丙烷偶合溶劑聯合使用的另 一種惰性有機溶劑,例如THF、甲苯、2-曱基THF,或二 曱氧基乙烷。 200904810 酉曰化」意為從缓酸基向其對應酯的轉化。 「偶合劑」意為一種選自cdi、dcc、pfp、h〇b1^ HBTU等用於實現酯化反應的化合物。 「水解助溶劑」意為一種惰性極性有機溶劑,例如一 種醚’如1,4_二喔炫、叔丁基曱基鍵(丁舰£)、異丙基乙 基醚以及二乙醚。 「鹼性水解」意為使用鹼金屬的氫氧化物例如鋰、鈉 或鉀的氫氧化物或鹼土金屬的氫氧化物以實現水解。 「硬化劑」意為12、二蛾乙烯、,或ΝΒΙ。 「碘化」意為在一種強鹼存在條件下與一種碘化劑進 行反應。 非貝子極性溶劑」意為一種溶劑,例如乙鍵、叔丁 基曱基_ ( TBME )、異丙基乙基醚、thf、1,4-二噪烧或 1,3-二氧戊烧等。 「烴溶劑」意為一種溶劑例如曱苯、二甲苯或庚烷等。 「鹵代烴溶劑」意為一種匚3_5鹵(首選的是氟或氯) 代烴,例如氯仿或二氯曱烧。 (月性/谷刻」思為一種非質子極性溶劑、煙溶劑、鹵 代經〉谷劑、腈類〉谷劑如乙腈,或有機酸溶劑如乙酸或丙酸。 「強鹼」意為一種鹼金屬的鹼,例如NaH、NaHMDS、 KHMDS'LiHMDS、二異丙醯胺鋰(LDA),或烷基金屬鹼, 例如烷基鋰、烷基鉀、烷基鈉和烷基鎂,其中該烷基是c16 脂環烷基(直鏈的、支鏈的或環烷基),更為首選的是丁基。 「叔胺驗」思為一種C! _5有機驗,其中的氮不帶氫原 -12- 200904810 子,例如三乙胺。 【實施方式】 在依照本發明之方法的一個具體實施例中,碘化是在 5 THF中實現的。 在依照本發明之方法的另一具體實施例中,碘化所用 的強驗是LDA。 在依照本發明之方法的另一具體實施例中,碘化劑是 12。 ίο 在依照本發明之方法的另一具體實施例中,碘化是於 約-80°C至約0°C的溫度條件下實現的。 在依照本發明之方法的另一具體實施例中,鹼金屬丙 醇鹽是NaOPr。 在依照本發明之方法的另一具體實施例中,銅催化劑 15 是 Cul。 在依照本發明之方法的另一具體實施例中,取決於所 用溶劑和所用壓力,偶合反應是於約70°C至約120°C的加 熱條件下實現的。 在依照本發明之方法的另一具體實施例中,與C02的 2〇 偶合反應所用的溶劑是THF。 在依照本發明之方法的另一具體實施例中,與C02的 偶合反應所用的強鹼是正丁基鋰。 在依照本發明之方法的另一具體實施例中,與C02的 偶合反應是在低於-14°C溫度條件下進行的,更首選的溫度 -13 - 200904810 是從约-22°C至約-i4〇c。 在依照本發明之方法的另一具體實施例中 的溶劑是二氯甲烧。 在依恥本發明之方法的另一具體實施例中 的偶合劑是羰基二咪唑。 在依照本發明之方法的另一具體實施例中 約為室溫的條件下進行的。 在依照本發明之方法的另一具體實施例中 惰性溶劑是IS代烴;更為首選的是二氯曱烷。 在依照本發明之方法的另一具體實施例中 約〇°C至約1〇〇。(:的溫度條件下實現的。 在依照本發明之方法的另一具體實施例中NaOPr, LiOPr or KOPr. "Amidoxime coupling" means the formation of a coupling reaction of guanamine. "Bromide" means a source of bromine, such as Br2 or NBS. "Copper catalyst" means a copper catalyst capable of promoting a Ullmann coupling reaction selected from the group consisting of CuSCN, CuBr, Cul, Cua, CuBF4, CuPF6, CuOTf, CuPF6, CuBr2, CuCl2, and Cu20. "Coupling cosolvent" means another inert organic solvent which can be used in combination with a propane coupling solvent such as THF, toluene, 2-mercaptoTHF or dimethoxyethane. 200904810 "Deuteration" means the conversion of a slow acid group to its corresponding ester. "Coupling agent" means a compound selected from the group consisting of cdi, dcc, pfp, h〇b1^ HBTU, etc. for effecting an esterification reaction. The "hydrolysis cosolvent" means an inert polar organic solvent such as an ether such as 1,4-dioxan, tert-butylfluorenyl bond (butyl), isopropylethyl ether and diethyl ether. "Alkaline hydrolysis" means the use of an alkali metal hydroxide such as a hydroxide of lithium, sodium or potassium or a hydroxide of an alkaline earth metal to effect hydrolysis. "Hardener" means 12, 2 moth ethylene, or hydrazine. "Iodination" means the reaction with an iodinating agent in the presence of a strong base. Non-shell-like polar solvent means a solvent such as ethyl bond, tert-butyl fluorenyl _ (TBME), isopropyl ethyl ether, thf, 1,4-dioxane or 1,3-dioxane, etc. . The "hydrocarbon solvent" means a solvent such as toluene, xylene or heptane. "Halohydrocarbon solvent" means a hydrazine 3_5 halogen (preferably fluorine or chlorine) hydrocarbon, such as chloroform or dichlorohydrazine. (Monthly/Valley) is an aprotic polar solvent, a smoke solvent, a halogenated gluten, a nitrile, a gluten such as acetonitrile, or an organic acid solvent such as acetic acid or propionic acid. a base of an alkali metal such as NaH, NaHMDS, KHMDS'LiHMDS, lithium diisopropylamide (LDA), or an alkyl metal base such as an alkyl lithium, a potassium alkyl group, a sodium alkyl group and an alkyl magnesium, wherein the alkane The base is a c16 alicyclic alkyl group (linear, branched or cycloalkyl), and more preferred is butyl. "Terminal amine test" is a C! _5 organic test, in which the nitrogen does not have a hydrogen source. -12- 200904810 Sub, for example triethylamine. [Embodiment] In a specific embodiment of the method according to the invention, iodination is carried out in 5 THF. Another embodiment of the method according to the invention In the other embodiment of the method according to the invention, the iodinating agent is 12. ίο In another embodiment of the method according to the invention, iodination is Achieved at a temperature of from about -80 ° C to about 0 ° C. Another embodiment of the method according to the invention The alkali metal propoxide is NaOPr. In another embodiment of the process according to the invention, the copper catalyst 15 is Cul. In another embodiment of the method according to the invention, depending on the solvent used and the pressure used The coupling reaction is carried out under heating at a temperature of from about 70 ° C to about 120 ° C. In another embodiment of the process according to the invention, the solvent used for the coupling reaction with CO 2 is THF. In another embodiment of the process of the invention, the strong base used in the coupling reaction with CO 2 is n-butyllithium. In another embodiment of the process according to the invention, the coupling reaction with CO 2 is below - The temperature preferred at 14 ° C, the preferred temperature -13 - 200904810 is from about -22 ° C to about -i 4 〇 c. The solvent in another embodiment of the method according to the invention is chloroform. The coupling agent in another embodiment of the method of the invention is carbonyldiimidazole. In another embodiment of the method according to the invention, it is carried out at about room temperature. Another method of the invention The inert solvent in the particular embodiment is an IS-based hydrocarbon; more preferred is dichlorodecane. In another embodiment of the method according to the invention, from about 〇 ° C to about 1 Torr. Implemented in another embodiment of the method according to the invention

Br2。 在依照本發明之方法的另一具體實施例中 合所用的醇溶劑是乙醇。 在依照本發明之方法的另一具體實施例中 合是於約室溫至約30°C的溫度條件下進行的。 在依照本發明之方法的另一具體實施例中 合所用的驗是三乙胺。 在依照本發明之方法的另一具體實施例中 應是用鹼的水溶液、Na0H水溶液進行的。 在依照本發明之方法的另一具體實施例中 應是於約5°C至約30°C的溫度條件下進行的。 ,用於酯化 ,用於酯化 ,酯化是於 ,漠化用的 ,溴化是於 ,溴化劑是 醯胺化偶 臨·胺化偶 醯胺化偶 脫保護反 脫保護反 -14- 200904810 實例 製備細節 原料可以購入或通過應用或改進已知的方法來製備, 或利用它們顯然的化學等效物。 5 通過參考以下本發明典型的非限制性實例,本發明可 更好地得到理解。提供以下實例是為了更充分地說明本發 明的具體實施例。然而,它們無論如何不應被理解為是限 制本發明的寬廣範圍。 在下文列出的核磁共振光譜(NMR)中,化學位移以 ίο ppm表示,以四曱基矽烷為内標。諸縮寫具有下列含義: br=寬峰,dd=雙峰,s=單峰;m=多重峰。 以下實例中所述的4-溴-3-曱基-5-丙氧基噻吩-2-羧酸 2,5-二氧吡咯烷-1-基酯的合成可以如下示意圖I表示。Br2. In another embodiment of the method according to the invention the alcohol solvent used is ethanol. In another embodiment of the method according to the invention, the reaction is carried out at a temperature of from about room temperature to about 30 °C. In another embodiment of the method according to the invention, the test used is triethylamine. In another embodiment of the process according to the invention it is to be carried out with an aqueous base solution, aqueous NaHH solution. In another embodiment of the method according to the invention it should be carried out at a temperature of from about 5 ° C to about 30 ° C. For esterification, for esterification, esterification is used for desertification, bromination is, brominating agent is amide amination, amination, amination, oximation, deprotection, deprotection, anti-deactivation 14-200904810 EXAMPLES Preparation Details Raw materials can be purchased or prepared by applying or modifying known methods, or utilizing their apparent chemical equivalents. 5 The present invention will be better understood by reference to the following typical non-limiting examples of the invention. The following examples are provided to more fully illustrate the specific embodiments of the invention. However, they should not be construed as limiting the broad scope of the invention in any way. In the nuclear magnetic resonance spectroscopy (NMR) listed below, the chemical shift is expressed in ίο ppm and the tetradecyl decane is used as an internal standard. The abbreviations have the following meanings: br = broad peak, dd = doublet, s = singlet; m = multiplet. The synthesis of 4-bromo-3-indolyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxapyrrolidin-1-yl ester described in the following examples can be represented by the following scheme I.

15 不意圖I ^^ONa15 not intended I ^^ONa

-15- 200904810 實例1 ·· 2-碘-4-曱基噻吩 向一個設有頂部攪拌器、橡膠隔膜、熱電偶以及氮氣 進/出口的3升4頸燒瓶加入3_甲基噻吩(135 mL,1.38 mol) 和THF ( 1 L)。將該混合物冷卻至-20〇C並通過12號(12 gauge)導管在一段35分鐘的時間内加入LDA (8〇〇mL溶 於THF/庚烧/乙苯的Aldrich 2.5 Μ溶液),調節添加速率並 根據必要冷卻,以將反應溫度維持在-25。(:和-15°C之間。 添加結束後,將該混合物攪拌3〇分鐘,將溫度維持在〇 〇c 以下。 10-15- 200904810 Example 1 · 2-Iodo-4-mercaptothiophene Add a 3-methylthiophene (135 mL) to a 3-liter 4-neck flask equipped with an overhead stirrer, rubber septum, thermocouple, and nitrogen inlet/outlet. , 1.38 mol) and THF (1 L). The mixture was cooled to -20 ° C and LDA was added via a 12 gauge (12 gauge) tube over a 35 minute period (8 〇〇 mL of Aldrich 2.5 Μ solution in THF / hexane / ethylbenzene). The rate was cooled as necessary to maintain the reaction temperature at -25. (: between -15 ° C. After the end of the addition, the mixture is stirred for 3 minutes and the temperature is maintained below 〇 〇 c. 10

在另一設有頂部攪拌器、冷浴、氮氣流和熱電偶的5 升,瓶中’將硬(454 g,1.3當量)溶於THF (1.65 L), 於至脈攪拌20分鐘以確保完全溶解並冷卻至-2〇〇c。當溶 液冷卻至-10°C時,碘開始析出。 讓該陰離子溶液升溫至並通過導管在40分鐘期間 加入,的’根據需要調節添加速率以將反應溫度維持 在]5°C或以下。當添加結束時,讓該混合物於2小時内升 溫至10°C。將反應物用MTBE (1〇L)稀釋並用半飽和氯 化銨⑽mL)終止反應。用G5 N琉代硫酸納(2 X… 任有機層在-分_内靜止4小時並抽出所有分離 水。將有機層於175 mbar的條件下通過 =至1.2 L。HPLC分析在水相或鶴出液均= 出產物。少量和無法定量的未反應Μ基㈣在洗== -16- 20 200904810 = ,回收的原料、不合格異構體的形成, > 1 疋轉•發顧出液中均不存在產物的事實’出 合反應試劑的目❾,計算出此反應的 為 73%。 密集多重峰),6.91 ( 1H, 1hnmr(cdci3,5)7〇5(1Hj 密集多重峰),(2.21,3H,s)。 實例2: 4-曱基-2-丙氧基噻吩 10 20 在設有迪安〜斯達克分水器、(Dean_starktrap)以及頂 部回流式冷㈣1部髮器、社㈣熱電偶以及氮氣 進/出口的3 = 3職瓶中,將實例丨所得溶液i 2 l與正 丙院(1 L)此δ將该混合物加熱至回流並抽出德出液, 並用正丙烧部分置換(約除去UL並加入5〇〇mL正丙烧) 直至液上空間溫度相%將該混合物冷卻至,c並 加入固體叔丁醇鈉(192 g,2 m。卜約2當量),放熱導致 升溫至約75 °C。將該混合物維持在乃和85〇(:之間,直至 所有固體全部溶解。再將反應混合物冷卻至5〇。〇 ’加入剛 製備的碘化銅1 (10〇mmo卜Bg)在正丙烷(5〇ml)中的 漿料。將該混合物加熱至95 cC。達到反應溫度3〇分鐘後 HPLC分析顯示反應已完全。用庚炫(1L)稀釋該混合物。 加入矽藻土(190 g) ’將生成的漿料攪拌6〇分鐘同時冷卻 至室溫。過濾該混合物並用庚烷(500 mL)洗滌濾餅。依 次用 5%EDTA 二鈉水溶液(3X500mL)、水( 3 x 500 mL) 碘化銅是在研蛛中剛研磨的並以正丙烷漿料的形式超聲處理5分鐘。 -17- 200904810 和鹽水( 500 mL)洗滌該濾液和洗滌液,即得一顏色很深 的有機層,將其濃縮至<200 mL ( 170 mbar,60。〇,即得 159 g深棕色液體’以iHNMR分析即為51A%所需的化合 物。主要的雜質是庚烷、乙苯(來自於購入的LDa)及2_ 埃-3 -甲基1^塞吩。 4 NMR ( CDC13 ’ δ) 6.18 ( 1H,d) ; 6.02 ( 1H,d) ; 3.98 (2H ’ t) ; 2.15 (3H ’ S) ; 2.80 (2H,m) ; 1.05 (3H,t)。 實例3 : 3-甲基-5-丙氧基噻吩_2_羧酸 15 20 將實例2的粗製4-甲基-2-丙氧基噻吩(計算值79 g, 506 mmol)轉移至設有頂部攪拌、熱電偶、氮氣進口/出口, 壓力平衡滴液漏斗和橡膠隔膜的2升3頸燒瓶中,並用600 mL THF稀釋。將該混合物冷卻至_22〇c,將2 5 μ正丁基 鋰(283 mL,1·4當量)的庚烧溶液通過加料漏斗在μ分 鐘内以,加方式迅速加入,溫度範圍為-22至-14。。,穩定 在約_21:C。3。分鐘後,將溫度維持在七。c以下,反應混 ^物取樣分析(經秘麟)顯示約化。使二氧化 :^5。。進·^合物中’控制氣體流量以維持反應溫度低 降1 C〇2直至不再放熱且反應溫度開始下 ^ 里虱化鈉水溶液(600 mL·)終止反應並加入矽 冻 t $ g)將该混合物擾拌30分鐘並用濾、布過濾、。用 〇:5^氫^化納(3GmL)洗誠餅。合併遽液和洗務液後 得ΓΪ掠色溶液,用庚烧(3 X 200 mL)洗務。將水相pH 值《周#至為6.8 ’此時形成枯稠狀稼色/黑色焦油。將該溶 -18- 200904810 45,ίρ得大% Γ —淡掠色濾液。將PH值繼續調節至 洗、/二冗趨,用濾布過據,用冰水⑽虹) ;二3 h内風乾再用真空峨燥(12小時, 黃色固體⑷」g,^) 减麵,2邊酸,為米 1HNMR(CDCl3,a),12〇H,s);^ (3H,s),l_82 (2H ’ m) ; 1.05 ⑽,t)。 實例4 : 3_甲基_5爾基餘2_舰2,5二氧轉从基醋 在设有頂部攪拌、冷浴、熱電偶和氮氣進/出口的2升 3頸燒瓶中加人3_甲基_5_丙氧基嗟吩_2_舰(85 〇 g,似 聰〇1)、N-琥舰亞胺(68_3 g,! ·4 #量)和二氯甲烧(7〇〇 mL) ’於室溫下攪拌。混合時放熱且溫度上升3。匚,生成一 種棕色溶液。冷浴内盛有室溫的水,只用於吸收輕微的放 熱。分4批每隔1〇分鐘加入26_〇 g固體羰基二咪唑 〇〇4 g,1.1當量)。每次添加都將出現2_3C>C的升溫及氣 體的緩慢釋放。在最後一次添加完畢後,將該混合物於室 溫下攪拌3小時或攪拌過夜。用半飽和氯化銨(2〇〇 mL) 終止該混合物的反應並用水(3 X 150 mL)和鹽水(150 mL) 洗蘇。在170 mbar和30°C的條件下,通過與庚烧的溶劑交 換分離出產物。生成固體後,先後將該混合物冷卻至室溫 和5°C ’即得一種亮黃色固體’用濾布過濾分離,用庚烧洗 務,在玻璃器皿内風乾20分鐘後再進一步真空乾燥(3〇 °C’ 1.5英寸Hg柱),即得3-曱基-5-丙氧基噻吩_2_羧酸2,5- -19· 200904810 二氧吼51 各烧-1-基S旨(i〇4 g,83%)。 >JMR (CDC13 ’ δ) 6.20 ( 1H,s) ; 4.05 (3H,t) ; 2_95 (4H,s) ; 2.51 (3H,s) ; 1.82 (2H,m) ; 1.05 (3H,t)。 5 實例5 : 4_溴_3_曱基-5-丙氧基噻吩-2-羧酸2,5-二氧吡咯烷 -1 -基酯 在設有熱電偶、冰浴和頂部攪拌的2升3頸圓底燒瓶 加入3-甲基-5-丙氧基噻吩羧酸2,5_二氧吡咯烷小基酯 (81 g,273 mmol)、異丙醇(5〇〇 mL)和 DCM ( 350 mL), 10 即得一種非常稀的漿料。將該混合物冷卻至<5QC,在4至 11 °C的溫度範圍内以滴加方式加入溴(22 mL,328 mmol, 1.2當量)的庚烷(80 mL)溶液。將此很稀的漿料進一步 稀釋,但該混合物未完全均化。在—段19分鐘的時間内加 入溶劑,待反應完成時進行分析。用DCM (600 mL)稀釋 15 反應物並用1 #硫代硫酸鈉(250 mL)終止反應。用水(2 X 350 mL)洗滌有機層。此時HPLC分析顯示約有6 3%原 料未反應。這大概是由於原料附在玻璃器孤上,使它在溶 液分析時未被測出。將有機相乾燥(Na2S04 )和濃縮(30 °C ’ 125 mbar) ’即得一種棕色固體,將其再溶於DCm( 7〇〇 2〇 mL)並於5°C用漠(4 mL ’ 78 mmol,0.3當量)的庚烧(20 mL)溶液處理以完成反應。將有機相在25〇mL丨#硫代硫 酸鈉( 250 mL)水溶液中分配,並用水(2x25〇mL)和鹽 水( 250 mL)洗滌。將溶劑體積(3〇0C,125mbar)縮小 至300 mL·並加入400 mL庚烧(達到某種程度的結晶)。通 -20- 200904810 過旋轉蒸發將該混合物濃縮至乾,即得104§棕色固體。將 粗製產物從回流IPA ( 500 mL)中再結晶並乾燥(4〇 〇c, 1.5英寸Hg柱),即得93g4-溴-3-甲基-5-丙氧基噻吩_2_羧 酸2,5-二氧吼咯烧-1-基酯,為褐色固體(Μ%)。 NMR (CDC13 ’ δ) 4.19 (2H,t) ; 2.92 (4H,s) ; 3.59 (3H ’ s) ; 1.95 ( 2H,m) ; 1·〇8 ( 3H,t)。 實例6: [4_〇胺基甲基氟笨基)_狐啶小基]_(4U_曱基 -5-丙氧基。塞吩-2-基)-甲酮 在一個5升3頸圓底燒瓶中加入2,2,2-三氟-N-(4-氟-3-呱啶-4-基苯甲基)-乙醯胺鹽酸鹽(176.7g,0.518mol)和 1.51 L無水EtOH。攪拌該混合物並加入三乙胺(215 mL , 1.55 mol)。將該混合物擾拌3分鐘,然後加入4-漠_3_曱基 -5-丙氧基噻吩-2-羧酸2,5-二氧吡咯烷-1-基酯(194 g,0.516 mol) ’放熱導致該混合物升溫至26 %。將反應混合物擾拌 18小時,然後在丨.5 l水和1.5 LTBME之間分配。依次用 水(2x〇.5L)、1NHC1 (0.5L)水溶液和鹽水(0.2L)洗 滌有機相。讓深琥轴色有機相通過一短Si〇2墊(h:=().5,,, Φ=3,5”)過濾,用0.3 LEtOAc洗脫。未見顏色顯著減弱。 將該溶液冷卻至7DC,加入194 mL 50% NaOH水溶液,放 熱導致該混合物升溫至24。0 3小時後,依次用水(2x 1 L, 1 x〇_8L)和鹽水(0.5 L)洗滌該混合物,然後用硫酸鈉乾 燥該有機相。將該溶液冷卻至13。(:,以滴加方式加入4 N HC1的1,4-二噁烷溶液(135 mL,0.54 mol)。將該混合物 -21 - 200904810 攪拌3小時,然後經過濾分離產物(相當緩慢),用ΜΤΒΕ 洗滌並用空氣乾燥15小時,即得130.2 g (50%) [4-(5-胺 基曱基-2-氟苯基)-呱啶-1 -基]-(4-溴-3-曱基-5-丙氧基噻吩 -2-基)-甲酮,為淡米黃色固體。In another 5 liter bottle with a top stirrer, cold bath, nitrogen flow and thermocouple, 'hard (454 g, 1.3 equivalents) in THF (1.65 L), stir for 20 minutes to ensure completeness Dissolve and cool to -2 °c. When the solution was cooled to -10 ° C, iodine began to precipitate. The anion solution was allowed to warm up and was added over a 40 minute period through a conduit, and the rate of addition was adjusted as needed to maintain the reaction temperature at < 5 ° C or below. When the addition was complete, the mixture was allowed to warm to 10 °C over 2 hours. The reaction was diluted with MTBE (1 mL) and quenched with semi-saturated ammonium chloride (10 mL). Use G5 N deuterated sodium sulphate (2 X... Leave the organic layer in-minute for 4 hours and extract all the separated water. Pass the organic layer at 175 mbar through = to 1.2 L. HPLC analysis in the aqueous phase or crane The output is = product. A small amount and unquantified unreacted sulfhydryl group (4) in the wash == -16- 20 200904810 = , the recovered raw materials, the formation of the unqualified isomers, > 1 疋 转 • The fact that there is no product in the middle of the 'reaction reaction reagent, the reaction is calculated to be 73%. Dense multiple peaks), 6.91 (1H, 1hnmr(cdci3,5)7〇5 (1Hj dense multiplet), ( 2.21, 3H, s). Example 2: 4-mercapto-2-propoxythiophene 10 20 In the presence of Dean ~ Stark trap, (Dean_starktrap) and top reflux type cold (four) 1 hair machine, (4) In the 3 = 3 bottle of thermocouple and nitrogen inlet/outlet, the solution obtained by the example i i 2 l and the positive propylene (1 L) δ The mixture is heated to reflux and the effluent is extracted, and the propylene is burned. Partial displacement (about UL removal and addition of 5 〇〇 mL of n-propyl) until the liquid space temperature phase % cooled the mixture to c, and added solid tert-butyl Sodium (192 g, 2 m. about 2 equivalents), exotherm causes the temperature to rise to about 75 ° C. The mixture is maintained between 85 ° and , until all solids are dissolved. The reaction mixture is then cooled to 5 〇 〇 'Add a slurry of freshly prepared copper iodide 1 (10 〇 mmo b Bg) in n-propane (5 〇 ml). The mixture was heated to 95 c C. After reaching the reaction temperature for 3 〇 minutes, HPLC analysis showed The reaction was complete. Dilute the mixture with heptane (1 L). Add diatomaceous earth (190 g) 'The resulting slurry was stirred for 6 min while cooling to room temperature. The mixture was filtered and washed with heptane (500 mL) The cake was sequentially 5% EDTA in di-sodium azide (3X500 mL), water (3 x 500 mL). Copper iodide was just ground in a spider and sonicated for 5 minutes in the form of a n-propane slurry. -17- 200904810 and The filtrate and washings were washed with brine (500 mL) to give a dark organic layer, which was concentrated to <200 mL (170 mbar, 60 〇, 159 g of dark brown liquid, i. The required compound is 51A%. The main impurities are heptane and ethylbenzene (from purchased LD) a) and 2_ ang-3-methyl 1 thiophene. 4 NMR (CDC13 ' δ) 6.18 ( 1H, d) ; 6.02 ( 1H, d) ; 3.98 (2H ' t) ; 2.15 (3H ' S) ; 2.80 (2H,m) ; 1.05 (3H,t). Example 3: 3-Methyl-5-propoxythiophene-2-carboxylic acid 15 20 The crude 4-methyl-2-propoxythiophene of Example 2 (calculated 79 g, 506 mmol) was transferred to Top stir, thermocouple, nitrogen inlet/outlet, pressure balanced dropping funnel and rubber septum in a 2 liter 3-neck flask and diluted with 600 mL THF. The mixture was cooled to _22 〇c, and 25 μg of n-butyllithium (283 mL, 1.4 eq.) of heptane was added through an addition funnel in μ minutes, and the temperature range was -22. To -14. . , stable at about _21:C. 3. After a minute, the temperature is maintained at seven. Below c, the reaction mixture sampling analysis (by Mirin) shows reduction. Make the dioxide: ^5. . In the compound, the gas flow rate is controlled to maintain the reaction temperature drop by 1 C〇2 until no more exotherm occurs and the reaction temperature begins to lower the sodium bismuth solution (600 mL·) to terminate the reaction and add 矽 frozen t $ g) The mixture was spoiled for 30 minutes and filtered through a filter or cloth. Use 〇: 5 ^ hydrogen ^ sodium (3GmL) washed cake. After combining the sputum and the washing solution, the glaring solution was obtained and washed with g-burn (3 X 200 mL). The pH of the aqueous phase "Week # to 6.8" at this time formed a thick crop/black tar. The solution -18-200904810 45, ίρ gets a large % Γ - lightly plucked the filtrate. Continue to adjust the pH to wash, / two redundancy, use the filter cloth to pass the data, use ice water (10) rainbow); air dry in 2 3 h and then vacuum dry (12 hours, yellow solid (4)" g, ^) 2, acid, 1H NMR (CDCl3, a), 12 〇 H, s); ^ (3H, s), l_82 (2H 'm); 1.05 (10), t). Example 4: 3_Methyl _5 ergyl 2 s 2,5 dioxo ketone added to a 2 liter 3-neck flask with overhead stirring, cold bath, thermocouple and nitrogen inlet/outlet. _Methyl _5_propoxy porphin_2_ ship (85 〇g, like Cong 〇 1), N-Hui imine (68_3 g,! · 4 #量) and chloroform (7〇) 〇mL) 'Stir at room temperature. It exotherms when mixing and the temperature rises by 3. Oh, a brown solution is formed. The cold bath contains room temperature water and is only used to absorb a slight exotherm. In 4 batches, 26 g of solid carbonyl diimidazole 〇〇 4 g, 1.1 equivalents were added every 1 minute. The temperature rise of 2_3C>C and the slow release of the gas will occur each time it is added. After the last addition, the mixture was stirred at room temperature for 3 hours or stirred overnight. The reaction of the mixture was quenched with half-saturated ammonium chloride (2 mL) and washed with water (3 X 150 mL) and brine (150 mL). The product was isolated by exchange with a solvent of heptane at 170 mbar and 30 °C. After the solid was formed, the mixture was cooled to room temperature and 5 ° C to give a bright yellow solid. The mixture was filtered off with a filter cloth, washed with heptane, air-dried in a glassware for 20 minutes, and then further vacuum dried (3 〇 °C' 1.5 inch Hg column), that is, 3-mercapto-5-propoxythiophene-2-carboxylic acid 2,5--19·200904810 dioxin 51 each -1-yl group S (i〇 4 g, 83%). >JMR (CDC13' δ) 6.20 (1H, s); 4.05 (3H, t); 2_95 (4H, s); 2.51 (3H, s); 1.82 (2H, m); 1.05 (3H, t). 5 Example 5: 4_Bromo-3-yl-nonyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxapyrrolidin-1 -yl ester in a thermocouple, ice bath and top stir 2 A 3-neck round bottom flask was charged with 2-methyl-5-propoxythiophenecarboxylic acid 2,5-dioxopyrrolidine small ester (81 g, 273 mmol), isopropanol (5 〇〇 mL) and DCM. (350 mL), 10 gives a very dilute slurry. The mixture was cooled to <5QC, and a solution of bromine (22 mL, 328 mmol, 1.2 eq.) in heptane (80 mL) was added dropwise over a temperature range of 4 to 11 °C. This very dilute slurry was further diluted, but the mixture was not completely homogenized. The solvent was added over a period of 19 minutes and analyzed when the reaction was completed. The 15 reaction was diluted with DCM (600 mL) and quenched with 1N sodium thiosulfate (250 mL). The organic layer was washed with water (2×350 mL). HPLC analysis at this time showed that approximately 6 3% of the original material was unreacted. This is probably due to the fact that the material is attached to the glass so that it is not detected during solution analysis. Drying the organic phase (Na2S04) and concentrating (30 °C '125 mbar)' gave a brown solid which was redissolved in DCm (7 〇〇 2 〇 mL) and used at 5 ° C (4 mL ' 78 A solution of mmol, 0.3 eq. of heptane (20 mL) was taken to complete the reaction. The organic phase was partitioned between 25 mL of EtOAc (EtOAc) (EtOAc) (EtOAc) The solvent volume (3 〇 0 C, 125 mbar) was reduced to 300 mL· and 400 mL of heptane was added (to some degree of crystallization). -20-200904810 The mixture was concentrated to dryness by rotary evaporation to give 104 s brown solid. The crude product was recrystallized from refluxing IPA (500 mL) and dried (4 〇〇c, 1.5 inch Hg column) to give 93 g of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2 , 5-dioxopyrrole-1-yl ester, as a brown solid (Μ%). NMR (CDC13' δ) 4.19 (2H, t); 2.92 (4H, s); 3.59 (3H s s); 1.95 (2H, m); 1·〇8 (3H, t). Example 6: [4_Amidinomethylfluorophenyl]-foxidine small group]_(4U_indolyl-5-propoxy.cephen-2-yl)-methanone in a 5 liter 3 neck Add 2,2,2-trifluoro-N-(4-fluoro-3-acridin-4-ylbenzyl)-acetamide hydrochloride (176.7 g, 0.518 mol) and 1.51 L to a round bottom flask. Anhydrous EtOH. The mixture was stirred and triethylamine (215 mL, 1.55 mol) was added. The mixture was spoiled for 3 minutes and then 2,5-dioxapyrrolidin-1-yl 4-yl-3-indolyl-5-propoxythiophene-2-carboxylate (194 g, 0.516 mol) was added. The exotherm caused the mixture to warm to 26%. The reaction mixture was spoiled for 18 hours and then partitioned between 丨5 l water and 1.5 L TBME. The organic phase was washed successively with water (2 x 〇.5 L), 1 NHC1 (0.5 L) aqueous solution and brine (0.2 L). The deep amber color organic phase was filtered through a short Si〇2 pad (h:=().5,,, Φ=3,5") and eluted with 0.3 L of EtOAc. No significant color reduction was observed. To 7DC, add 194 mL of 50% aqueous NaOH solution. The exotherm causes the mixture to warm to 24. After 3 hours, the mixture is washed with water (2x 1 L, 1 x 〇_8 L) and brine (0.5 L), then sulfuric acid. The organic phase was dried with sodium. The solution was cooled to 13. (:, 4N HCl in 1,4-dioxane (135 mL, 0.54 mol) was added dropwise. The mixture was stirred from 21 - 200904810 3 The product was isolated by filtration (relatively slow), washed with hydrazine and dried with air for 15 hours to give 130.2 g (50%) [4-(5-aminomercapto-2-fluorophenyl)-acridine- 1-Methoxy]-(4-bromo-3-indolyl-5-propoxythiophen-2-yl)-methanone as a pale beige solid.

Claims (1)

10 20 200904810 、申請專利範圍: L 丙购吩领酸2,5_:氧電小 2·申請專利範圍第1項之化合物的方法,包 ,—種存在條件τ在—種 烴溶劑中,用—_ 狂丨王/合μα 中用種峨化齊,這3_甲基嘯吩破化,以 生成2-破-4-曱基υ塞吩; 使用-種銅催化劑在丙醇中進行2养4_甲基售 吩與驗金屬丙醇鹽的烏爾曼偶合反應,以生^_ 甲基-2-丙氧基嗟吩; 在種非貝子極性溶劑或烴溶劑中用強驗使4_甲 基·2_丙氧基°塞吩與C〇2發生偶合反應,以生成3_ 甲基-5-丙氧基噻吩_2_羧酸; 在一種偶合劑存在條件下在-種非質子極性溶 劑、烴溶劑或鹵代烴溶劑中用N-琥珀醯亞胺將3_ 甲,-5-丙氧基噻吩_2_羧酸酯化,以生成甲基巧_ 丙氧基噻吩-2-羧酸2,5_二氧吡咯烷_丨_基酯;以及 在一種惰性溶劑中用一種溴化劑將3_甲基_5_丙 氧基噻吩-2-羧酸2,5_二氧吡咯烷基酯溴化,以 生成4-溴-3-曱基_5_丙氧基噻吩_2_羧酸2,5_二氧 吡咯烷-1-基g旨。 3.如中請專利範_2項之方法,其巾魏反應是在 THF中進行。 •23· 200904810 15 20 如申請專利範圍第2項之大^ 的強驗是LDA。、去’其中蛾化反應中所用 如申請專利範圍第2項之方如申請專利範圍第2 其=化劑是l2。 :销至_的溫度條:=的中峨化反應是於專利_第2項之方法,其中鹼金屬丙《是如申請專利範圍第2項之方 如申請專利範圍第2項之^ 銅催化劑是⑸。 70〇Γ w m 法,其中偶合反應是於約 H) L C的加熱條件下進行的。 應是在珊中進行的方去’其中與⑶2的偶合反 η. 第2項之方法,其中與⑶2的偶合反 應所用的強驗是正丁基鋰。 12. 如申請專利範圍第2項之方 應是在低於俄的’其中與C〇2的偶合反 奶至約]^ 以㈣’更首選的溫度是約 13. 如申請專利範圍第12項 处(:至約_14。^ 貞之方法’其中溫度範圍是約14·2ϊ=範圍第2項之方法,其中醋化是在二氣子15. ::=利範圍第2項之方法,其中偶合一16. 如申請專利範圍第2項之方法,其中酉旨化是於約室溫 4. 5. 6. 9. -24- 5 200904810 17. 18. 19. 20. 的條件下進行的。 如申睛專利範圍第2項之方法, 惰性溶劑是二氯曱烷。 其中用於溴化反應的 那f睛專利範圍第2項之方法 〇°c至约100%^、、θ ,其尹溴化反應是在约 νc的就度靶圍内進行的。 如申請專利範圍第2項之方 —括曰士 1 *貝之方法,其中溴化劑是Br2。 —種具有下式的3_甲基_5_丙氧基„塞吩领酸2,5_二氧 π比洛炫-1 -基醋,10 20 200904810 , the scope of application for patents: L buys the acid 2,5_: oxygen small 2 · the method of applying for the compound of the first item of the patent range, the package, the existence condition τ in the hydrocarbon solvent, with - _ 丨王/合μα used in the 峨 峨 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , 4_methyl-synthesis and Ullmann coupling reaction of metal propanolate to produce ^_methyl-2-propoxy porphin; in the non-sheller polar solvent or hydrocarbon solvent, strong test 4_ Methyl-2-propoxy-ceremonase is coupled with C〇2 to form 3-methyl-5-propoxythiophene-2-carboxylic acid; in the presence of a coupling agent, aprotic polarity Esterification of 3-methyl-5-propoxythiophene-2-carboxylic acid with N-succinimide in a solvent, a hydrocarbon solvent or a halogenated hydrocarbon solvent to form methyl _ propyloxythiophene-2-carboxylate Acid 2,5-dioxapyrrolidinyl ester; and 2,5-dioxypyrrole 3-methyl-5-propoxythiophene-2-carboxylic acid with a brominating agent in an inert solvent Bromination of an alkyl ester to form 4-bromo-3-indenyl _5_ _2_ thiophene carboxylic 2,5_-dioxo pyrrolidin-1-yl purpose g. 3. As in the method of Patent No. _2, the reaction of the towel is carried out in THF. •23· 200904810 15 20 The strong test of the second part of the patent application scope is LDA. For example, the method used in the mothification reaction is as in the second paragraph of the patent application scope. : The temperature of the pin to _: The neutralization reaction of = is the method of the patent _ 2, wherein the alkali metal C is the copper catalyst as in the second paragraph of the patent application scope, as in the second paragraph of the patent application scope Yes (5). The 70 〇Γ w m method in which the coupling reaction is carried out under heating of about H) L C . It should be carried out in the middle of the case where the coupling with (3) 2 is reversed η. The method of item 2, wherein the coupling with the coupling reaction of (3) 2 is n-butyl lithium. 12. If the second item of the patent application scope is 2, it is lower than the Russian 'the coupling with C〇2 to the milk to the approximate number ^ ^ ^ (4) 'The preferred temperature is about 13. If the patent application scope 12 Where: (to a method of about _14.^ 贞) where the temperature range is about 14.2 ϊ = range item 2, wherein vinegar is in the second neutron 15.:== range of the second item, wherein Coupling-16. The method of claim 2, wherein the treatment is carried out at about room temperature 4. 5. 6. 9. -24- 5 200904810 17. 18. 19. 20. For example, in the method of claim 2, the inert solvent is dichlorodecane. The method for the bromination reaction of the second aspect of the patent range 〇°c to about 100%^, θ, The bromination reaction is carried out in the target range of about νc. For example, in the second aspect of the patent application, the method of the scorpion 1*, wherein the brominating agent is Br2, a type having the following formula: Methyl _5_propoxy </ RTI> thiophene diacid 2,5-dioxy π pirox-1 - vinegar, -25- 200904810 七、指定代表圖: (一) 本案指定代表圖為:第(無)圖。 (二) 本代表圖之元件符號簡單說明: 無。 10 15 八、本案若有化學式時,請揭示最能顯示發明特徵的化學式: 益。 *、、、 20-25- 200904810 VII. Designation of representative drawings: (1) The representative representative of the case is: (No). (2) A brief description of the component symbols of this representative figure: None. 10 15 VIII. If there is a chemical formula in this case, please disclose the chemical formula that best shows the characteristics of the invention: Benefit. *, ,, 20
TW097111151A 2007-03-29 2008-03-28 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester, its regio-specific synthesis and intermediate thereto TW200904810A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90883907P 2007-03-29 2007-03-29

Publications (1)

Publication Number Publication Date
TW200904810A true TW200904810A (en) 2009-02-01

Family

ID=39530622

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097111151A TW200904810A (en) 2007-03-29 2008-03-28 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester, its regio-specific synthesis and intermediate thereto

Country Status (3)

Country Link
AR (1) AR065859A1 (en)
TW (1) TW200904810A (en)
WO (1) WO2008121669A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2556764T3 (en) * 2008-08-22 2016-01-20 Sanofi [4- (5-Aminomethyl-2-fluoro-phenyl) -piperidin-1-yl] - [7-fluoro-1- (2-methoxyethyl) -4-trifluoromethoxy-1H-indole-3-yl] methanone as inhibitor mast cell tryptase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2005000039A (en) * 2004-03-26 2005-10-31 Aventis Pharma Inc HYDROCHLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) - PIPERIDIN-1-IL] - (4-BOMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE

Also Published As

Publication number Publication date
AR065859A1 (en) 2009-07-08
WO2008121669A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
CA2512504C (en) Method for producing 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
US20050182055A1 (en) Preparation process
TW200900383A (en) Fluoropyrazole carbonitrile derivatives and method of producing the same, and fluoropyrazole carboxylic acid derivatives prepared from the fluoropyrazole carbonitrile derivatives and method of producing the same
CN104736532B (en) The method of improved production 5 (2,6 24 morpholine, 4 pyrimidine) 4 trifluoromethyl pyridine, 2 amine
TW200946484A (en) Method for producing fluoroacylacetatic acid derivatives, method for producing fluoropyrazole carboxylate derivatives, and method for producing fluoropyrazole carboxyylic acid derivatives
TW202021952A (en) Process for the preparation of a pde4 inhibitor
WO2018205919A1 (en) Method for synthesizing silodosin and intermediate thereof
CN101415694A (en) Process for preparing linezolid
CN102317248A (en) Process for producing optically active carboxylic acid
CN110891940A (en) Process for preparing pyrazole-4-carboxamide derivatives
CN104918912B (en) Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds
TW200904810A (en) 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester, its regio-specific synthesis and intermediate thereto
US20180319738A1 (en) Process for the synthesis of (+) and (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
CN103059098B (en) Preparation method of dutasteride
TW200904811A (en) Use of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester for preparing the tryptase inhibitor [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone
WO2021258979A1 (en) Preparation method for aromatic ether compound
CN105745191A (en) Method for preparing silodosin and intermediate thereof
CN102300839B (en) Method For Manufacturing Trans-{4-[(alkyl Amino) Methyl] Cyclohexyl} Acetic Ester
CN108794375A (en) A kind of pabishta intermediate and its synthesis and application
JP2769058B2 (en) Preparation of cyclopropane derivatives
CN109485567B (en) Clean preparation method of 4-hydroxymethylthiazole and intermediate thereof
CN103570724B (en) The synthetic method of ponatinib
CN115103839B (en) Process for producing compound and compound
JP2014510714A (en) Method for producing retigabine
JP2004010572A (en) Method for producing 4-trifluoromethylnicotinic acid or its salt